iTeos Therapeutics, Inc.

NasdaqGM:ITOS Stock Report

Market Cap: US$448.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

iTeos Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ITOS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 May 25SellUS$29,582,305RA Capital Management, L.P.Company3,684,466US$8.37
15 May 25BuyUS$38,685,562EcoR1 Capital, LLCCompany4,958,978US$8.00
14 May 25BuyUS$10,634,000Tang Capital Management, LLCCompany1,300,000US$8.18
14 May 25SellUS$7,430,988MPM BioImpact LLCCompany1,006,909US$7.38
14 May 25SellUS$4,737,163BioImpact Capital LLCCompany641,892US$7.38
13 May 25SellUS$5,079,339MPM BioImpact LLCCompany630,191US$8.06
13 May 25SellUS$5,079,339MPM BioImpact LLCCompany630,191US$8.06
13 May 25SellUS$18,062,543RA Capital Management, L.P.Company2,232,700US$8.09
13 May 25SellUS$3,238,024BioImpact Capital LLCCompany401,740US$8.06
30 Apr 25SellUS$1,470,000Tang Capital Management, LLCCompany200,000US$7.35

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ITOS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders279,1030.631%
General Public3,144,9447.11%
Hedge Funds10,688,97824.2%
Institutions30,092,37368.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.

Top Shareholders

Top 25 shareholders own 76.57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.2%
EcoR1 Capital, LLC
10,688,978US$108.5m0%4.69%
10.4%
BlackRock, Inc.
4,574,537US$46.4m1.45%no data
8.66%
Tang Capital Management, LLC
3,826,692US$38.8m0%1.56%
4.4%
Ridgeback Capital Management LLC
1,942,959US$19.7m34.7%16.17%
3.76%
The Vanguard Group, Inc.
1,664,161US$16.9m-3.61%no data
1.88%
Dimensional Fund Advisors LP
832,761US$8.5m-29.5%no data
1.87%
Boxer Capital Management, LLC
825,000US$8.4m0%3.53%
1.59%
Geode Capital Management, LLC
703,467US$7.1m8.22%no data
1.59%
BioImpact Capital LLC
702,311US$7.1m-59.8%60.96%
1.58%
OrbiMed Advisors LLC
700,000US$7.1m0%0.11%
1.38%
Marshall Wace LLP
611,649US$6.2m412%0.01%
1.36%
Renaissance Technologies LLC
602,100US$6.1m-6.74%0.01%
1.35%
Nantahala Capital Management, LLC
596,666US$6.1m106%0.33%
1.34%
State Street Global Advisors, Inc.
594,555US$6.0m2.16%no data
1.3%
DLD Asset Management, LP
576,655US$5.9m0%3.13%
1.28%
Newtyn Management, LLC
567,416US$5.8m0%0.56%
1.24%
LMR Partners LLP
550,000US$5.6m0%0.13%
1.24%
JP Morgan Asset Management
549,090US$5.6m-48.2%no data
1.13%
Alyeska Investment Group, L.P.
500,000US$5.1m0%0.02%
1.1%
Almitas Capital LLC
487,204US$4.9m77.1%0.83%
1.08%
Millennium Management LLC
477,189US$4.8m37%no data
0.79%
Susquehanna International Group, LLP, Asset Management Arm
348,788US$3.5m861%no data
0.7%
Stonepine Capital Management LLC
310,033US$3.1m182%1.33%
0.7%
Bank of America Corporation, Asset Management Arm
308,660US$3.1m71.4%no data
0.69%
Morgan Stanley, Investment Banking and Brokerage Investments
305,584US$3.1m94.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/30 10:13
End of Day Share Price 2025/08/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iTeos Therapeutics, Inc. is covered by 3 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael UlzBaird
Derek ArchilaWells Fargo Securities, LLC
Eva Fortea-VerdejoWells Fargo Securities, LLC